These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17652808)

  • 21. Anthrapyrazoles: true successors to the anthracyclines?
    Judson IR
    Anticancer Drugs; 1991 Jun; 2(3):223-31. PubMed ID: 1802016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
    Scully RE; Lipshultz SE
    Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment of non-islet cell tumor hypoglycemia in hepatocellular carcinoma with doxorubicin.
    Kampitak T
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):929-30. PubMed ID: 18278497
    [No Abstract]   [Full Text] [Related]  

  • 26. Monitoring of anthracycline-induced cardiotoxicity.
    Jannazzo A; Hoffman J; Lutz M
    Ann Pharmacother; 2008 Jan; 42(1):99-104. PubMed ID: 18094345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
    Mehta RS; Schubbert T
    J Natl Cancer Inst; 2008 May; 100(9):680; author reply 680-1. PubMed ID: 18445822
    [No Abstract]   [Full Text] [Related]  

  • 28. [Anthracycline antibiotics in treatment of neoplasms].
    Błaszczyk F; Kowalski DM
    Pol Merkur Lekarski; 1997 May; 2(11):331-5. PubMed ID: 9377684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines.
    Edwardson DW; Narendrula R; Chewchuk S; Mispel-Beyer K; Mapletoft JP; Parissenti AM
    Curr Drug Metab; 2015; 16(6):412-26. PubMed ID: 26321196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity.
    Menna P; Minotti G; Salvatorelli E
    Cell Biol Toxicol; 2007 Jan; 23(1):49-62. PubMed ID: 17031515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New iron chelators in anthracycline-induced cardiotoxicity.
    Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
    Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of anthracycline-induced cardiotoxicity: is there light at the end of the tunnel?
    Suter TM; Meier B
    Ann Oncol; 2002 May; 13(5):647-9. PubMed ID: 12075731
    [No Abstract]   [Full Text] [Related]  

  • 33. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
    Moreno-Aspitia A; Perez EA
    Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prodrugs of anthracyclines in cancer chemotherapy.
    Kratz F; Warnecke A; Schmid B; Chung DE; Gitzel M
    Curr Med Chem; 2006; 13(5):477-523. PubMed ID: 16515518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anthracycline war: no victor yet.
    Young P
    J Natl Cancer Inst; 2009 Sep; 101(17):1171-3. PubMed ID: 19706625
    [No Abstract]   [Full Text] [Related]  

  • 36. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
    Menna P; Salvatorelli E; Minotti G
    Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cardiotoxicity of anthracyclin antibiotics].
    Biskup P; Wozakowska-Kapłon B; Góźdź S
    Pol Arch Med Wewn; 2006 Jul; 116(1):687-93. PubMed ID: 17340977
    [No Abstract]   [Full Text] [Related]  

  • 38. [Profile of the anti-tumor effects of amrubicin, a completely synthetic anthracycline].
    Hanada M; Noguchi T; Murayama T
    Nihon Yakurigaku Zasshi; 2003 Aug; 122(2):141-50. PubMed ID: 12890900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines.
    Verma S; Dent S; Chow BJ; Rayson D; Safra T
    Cancer Treat Rev; 2008 Aug; 34(5):391-406. PubMed ID: 18358614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?
    Di Leo A; Biganzoli L; Claudino W; Licitra S; Pestrin M; Larsimont D
    Eur J Cancer; 2008 Dec; 44(18):2791-8. PubMed ID: 18993056
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.